- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01575795
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI): a Multi-center Randomized Parallel Pharmacodynamic Study.
This is a multi-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, performed at 3 institutions (Patras University Hospital; Evangelismos Athens General Hospital; Gennimatas Athens General Hospital).
Patients with ST elevation myocardial infarction (symptom onset < 12 hours), undergoing primary percutaneous coronary intervention, who are antiplatelet naïve (Group A) or present high residual PR (defined as PRU ≥ 208) immediately before primary percutaneous coronary intervention, will be randomized after informed consent, in a 1:1 ratio to either:
Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD )starting 12±6 hours post LD Or Ticagrelor 360mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD Platelet reactivity assessment will be performed at randomization (Hour 0) and at 0.5, 1, 2, 4 hours after randomization, using the VerifyNow assay, in platelet reactivity units (PRU).
Documentation of major adverse cardiac events (death, myocardial infarction, stroke, urgent revascularization procedure with PCI or CABG) and bleeding (according to Bleeding Academic Research Consortium criteria) will be performed until patient's discharge.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Achaia
-
Rio, Achaia, Griechenland, 26500
- Cardiology Department Patras University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years old
- Patients with STEMI (onset of pain < 12 hours) with indication for primary PCI
- Antiplatelet naïve or presenting HTPR (≥ 208 PRU) immediately before primary percutaneous coronary intervention
- Informed consent obtained in writing
Exclusion Criteria
- Pregnancy
- Breastfeeding
- Inability to give informed consent or high likelihood of being unavailable until the Day 5
- Cardiogenic shock
- Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
- Unsuccessful PCI (residual stenosis > 30% or flow < ΤΙΜΙ 3)
- Known hypersensitivity to ticagrelor
- History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.
- Other bleeding diathesis, or considered by investigator to be at high risk for bleeding
- Any previous history of stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
- Thrombocytopenia (< 100.000/μL) at randomization
- Anaemia (Hct < 30%) at randomization
- Polycytaemia (Hct > 52%) at randomization
- Periprocedural IIb/IIIa inhibitors administration
- Thrombolysis administration
- Recent (< 6 weeks) major surgery or trauma, including GABG.
- Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
- Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin/rifampicin, phenytoin, carbamazepine).
- Increased risk of bradycardiac events.
- Dialysis required.
- Severe uncontrolled chronic obstructive pulmonary disease
- Known severe hepatic impairment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Ticagrelor 180mg loading dose
|
Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
Ticagrelor 180mg loading dose 180mg loading dose
|
Experimental: Ticagrelor 360mg loading dose
|
Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
Ticagrelor 180mg loading dose 180mg loading dose
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
platelet reactivity at 1 hour post randomization in Group A, between the 2 treatment arms.
Zeitfenster: 1 hour
|
platelet reactivity at 1 hour post randomization in Group A, between the 2 treatment arms.
|
1 hour
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
1. Platelet reactivity at 1 hour post randomization in Group B, between the 2 treatment arms.
Zeitfenster: 1 hour
|
1. Platelet reactivity at 1 hour post randomization in Group B, between the 2 treatment arms.
|
1 hour
|
2. Platelet reactivity at 0.5 hour post randomization between the 2 treatment arms separately for Group A and B
Zeitfenster: 0.5 hour
|
Platelet reactivity at 0.5 hour post randomization between the 2 treatment arms separately for Group A and B
|
0.5 hour
|
Platelet reactivity at 2 hours post randomization between the 2 treatment arms separately for Group A and B
Zeitfenster: 2 hours
|
Platelet reactivity at 2 hours post randomization between the 2 treatment arms separately for Group A and B
|
2 hours
|
Platelet reactivity at 4 hours post randomization between the 2 treatment arms separately for Group A and B
Zeitfenster: 4 hours
|
Platelet reactivity at 4 hours post randomization between the 2 treatment arms separately for Group A and B
|
4 hours
|
3. High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 0.5 hour post randomization between the 2 treatment arms, separately for Group A and B
Zeitfenster: 0.5 hour
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 0.5 hour post randomization between the 2 treatment arms, separately for Group A and B
|
0.5 hour
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 1 hour post randomization between the 2 treatment arms, separately for Group A and B
Zeitfenster: 1 hour
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 1 hour post randomization between the 2 treatment arms, separately for Group A and B
|
1 hour
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 2 hours post randomization between the 2 treatment arms, separately for Group A and B
Zeitfenster: 2 hours
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 2 hours post randomization between the 2 treatment arms, separately for Group A and B
|
2 hours
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 4 hours post randomization between the 2 treatment arms, separately for Group A and B
Zeitfenster: 4 hours
|
High on treatment platelet reactivity (HTPR) rates (≥208 PRU) at 4 hours post randomization between the 2 treatment arms, separately for Group A and B
|
4 hours
|
Occurrence of any 5-day bleeding event (BARC Types 1-5)
Zeitfenster: 5 days
|
Occurrence of any 5-day bleeding event (BARC Types 1-5)
|
5 days
|
Occurrence of 5-day MACEs
Zeitfenster: 5 days
|
Occurrence of 5-day MACEs
|
5 days
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Dimitrios Alexopoulos, MD, University Hospital of Patras
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Ischämie
- Pathologische Prozesse
- Nekrose
- Myokardischämie
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Herzinfarkt
- Infarkt
- Myokardinfarkt mit ST-Hebung
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Thrombozytenaggregationshemmer
- Purinerge P2Y-Rezeptorantagonisten
- Purinerge P2-Rezeptorantagonisten
- Purinerge Antagonisten
- Purinerge Wirkstoffe
- Ticagrelor
Andere Studien-ID-Nummern
- PATRASCARDIOLOGY-10
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Ticagrelor
-
Federico II UniversityAdvicePharma GroupAbgeschlossenHerzinfarkt | Koronare Herzkrankheit | Akutes Koronar-Syndrom | STEMI | NSTEMIItalien
-
Collegium Medicum w BydgoszczyAbgeschlossen
-
University of FloridaAbgeschlossen
-
AstraZenecaParexelAbgeschlossen
-
AstraZenecaAbgeschlossenHerzinfarkt | Streicheln | Atherothrombose | Herz-Kreislauf-TodSchweden, Vereinigte Staaten, Australien, Brasilien, Bulgarien, Tschechische Republik, Frankreich, Italien, Korea, Republik von, Peru, Polen, Russische Föderation, Südafrika, Spanien, Truthahn, Vereinigtes Königreich, De... und mehr
-
Bio-innova Co., LtdNoch keine Rekrutierung
-
Centro Hospitalario La ConcepcionRekrutierung
-
Azienda Ospedaliero Universitaria di SassariAstraZenecaAbgeschlossenMyokardinfarkt mit ST-Hebung | NSTEMI – Nicht-ST-Streckenerhöhung MIItalien
-
Sheba Medical CenterAbgeschlossenMyokardinfarkt mit ST-Hebung | Akute KoronarsyndromeIsrael
-
David AntoniucciAstraZeneca; A.R. CARD Onlus FoundationAbgeschlossenAkutes Koronar-Syndrom | Nebenwirkung auf ThrombozytenaggregationshemmerItalien, Griechenland